Article Text
Letters to the editor
Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition
Statistics from Altmetric.com
Tetrabenazine (TBZ), a synthetic benzoquinolizine, was first introduced as a neuroleptic agent in 1960, and is now widely used in the treatment of hyperkinetic movement disorders such as chorea, tics, or tardive dyskinesia. The side effect profile is mainly characterised by the triad of drowsiness/fatigue, parkinsonism, and depression; depression is found in about 15% of patients treated with TBZ.1 We here report on the rapid reversal of depressive symptoms in a patient treated with TBZ for orofacial dystonia by administering the new and highly selective noradrenaline (norepinephrine) …